Progress in the Study of Drugs for Thrombolytic Therapy of Acute Myocardial Infarction
Cardiovascular Reviews · 2024
DOI: 10.26689/cr.v2i1.6583 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiovascular Reviews, 2024. Verfasst von Yayun Ling.
Abstract (Originalsprache)
Acute myocardial infarction has become a serious disease that affects the quality of contemporary human survival, and improved efficacy and risk avoidance can be achieved through the upgrading of thrombolytic drugs and precise intervention. This article takes the development of three generations of thrombolytic drugs as the main line, and combs through the development of thrombolytic drugs from the era of urokinase and streptokinase to Alteplase and single-chain urokinase-type fibrinogen activator and their respective advantages and disadvantages. The advantages of three generations of tissue-type fibrinogen kinase derivatives, Reteplase, and tenecteplase, are compared and described in this article.
Zitieren
APA
Ling, Y. (2024). Progress in the Study of Drugs for Thrombolytic Therapy of Acute Myocardial Infarction. Cardiovascular Reviews. https://doi.org/10.26689/cr.v2i1.6583
Vancouver
Ling Y. Progress in the Study of Drugs for Thrombolytic Therapy of Acute Myocardial Infarction. Cardiovascular Reviews. 2024. doi:10.26689/cr.v2i1.6583
BibTeX
@article{Ling2024,
author = {Ling, Yayun},
title = {Progress in the Study of Drugs for Thrombolytic Therapy of Acute Myocardial Infarction},
journal = {Cardiovascular Reviews},
year = {2024},
doi = {10.26689/cr.v2i1.6583}
}
EUVIMED